


## PHARMACEUTICAL 2018

## Oncolix Inc. Rank 325 of 349





## PHARMACEUTICAL 2018

## Oncolix Inc. Rank 325 of 349

The relative strengths and weaknesses of Oncolix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncolix Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 192% points. The greatest weakness of Oncolix Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 446% points.

The company's Economic Capital Ratio, given in the ranking table, is -902%, being 625% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	889
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,263
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,841
Other Liabilities	1,268
Other Net Income	437
Property and Equipment	0
Research and Development	463
Revenues	0
Selling, General and Administrative Expense	1,490

Output Variable	Value in 1000 USD
Assets	889
Liabilities	2,531
Expenses	3,794
Stockholders Equity	-1,642
Net Income	-3,357
Comprehensive Net Income	-3,357
Economic Capital Ratio	-902%